Gender |
0.017 |
|
|
Age (65 years) |
0.083 |
|
|
Tumor location |
0.149 |
|
|
Numbers of liver metastases |
0.322 |
|
|
CEA level |
0.003 |
0.007 |
3.056 (1.354–6.897) |
CA19‐9 level |
0.469 |
|
|
Extra‐nodal tumor deposits |
0.049 |
|
|
Lymphovascular invasion |
0.009 |
0.054 |
3.055 (0.981–9.512) |
Ascites |
0.165 |
|
|
Obstruction |
0.766 |
|
|
Treatment strategy |
<0.001 |
0.023 |
0.212 (0.056–0.808) |
CD133+ subpopulation |
0.069 |
|
|
CD54+ subpopulation |
0.931 |
|
|
CD44+ subpopulation |
0.966 |
|
|
CD133+CD44− subpopulation |
0.962 |
|
|
CD133+CD44+ subpopulation |
0.069 |
|
|
CD133−CD44+ subpopulation |
0.206 |
|
|
CD133+CD54− subpopulation |
0.981 |
|
|
CD133+CD54+ subpopulation |
<0.001 |
0.079 |
4.838 (0.834–28.078) |
CD133−CD54+ subpopulation |
0.004 |
|
|
CD54+CD44− subpopulation |
0.437 |
|
|
CD54+CD44+ subpopulation |
0.538 |
|
|
CD54−CD44+ subpopulation |
0.542 |
|
|
CD133+CD44+CD54− subpopulation |
0.165 |
|
|
CD133+CD44+CD54+ subpopulation |
0.003 |
0.014 |
6.459 (1.461–28.558) |
CD133+CD44−CD54+ subpopulation |
0.774 |
|
|